Working… Menu

Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00790647
Recruitment Status : Completed
First Posted : November 13, 2008
Results First Posted : February 6, 2017
Last Update Posted : February 6, 2017
Information provided by (Responsible Party):
Vaishali Sanchorawala, Boston Medical Center

Brief Summary:

RATIONALE: Giving melphalan and bortezomib before and after a stem cell transplant stops the growth of abnormal cells by stopping them from dividing or killing them. Giving colony-stimulating factors and certain chemotherapy drugs, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy and monoclonal antibody therapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.

PURPOSE: This phase II trial is studying how well giving melphalan together with bortezomib followed by stem cell transplant works in treating patients with primary systemic amyloidosis.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Biological: filgrastim Drug: bortezomib Drug: melphalan Procedure: Stem Cell Infusion Phase 2

Detailed Description:


  • To determine if hematologic responses to high-dose melphalan and autologous stem cell transplantation increase with addition of bortezomib in the conditioning regimen in patients with primary systemic amyloidosis.


  • Autologous stem cell mobilization and collection: Patients receive filgrastim to mobilize stem cells, which are then collected.
  • Conditioning regimen: Patients receive bortezomib intravenously on days -6, -3, 1, and 4 and oral high-dose melphalan on days -2 and -1.
  • Stem cell transplantation: Patients undergo autologous stem cell transplantation on day 0.

After completion of study therapy, patients are followed every 6 months for 1 year and annually thereafter.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis
Study Start Date : June 2008
Actual Primary Completion Date : December 2012
Actual Study Completion Date : November 2014

Arm Intervention/treatment
Experimental: Stem Cell Transplant with Bortezomib and Melphalan
Mobilization with Filgrastim Stem Cell Collection Bortezomib Melphalan Stem Cell infusion
Biological: filgrastim
16 mcg/kg daily beginning 3 days before stem cell collection through day before final stem cell collection
Other Name: Growth-Colony Stimulating Factor, neupogen

Drug: bortezomib
1.0 mg/m2/dose D -6, D-3, D +1, D + 4
Other Name: velcade

Drug: melphalan
100 mg/m2/dose D -2, D -1
Other Name: alkeran

Procedure: Stem Cell Infusion
infusion of previously collected autologous stem cells

Primary Outcome Measures :
  1. Number of Participants With Hematologic Response [ Time Frame: one year ]

    complete and partial hematologic response defined as: Complete response: absence of detectable monoclonal protein in serum and urine, and bone marrow biopsy <5% plasma cells with no clonal predominance of kappa or lambda isotype.

    Partial response: any one of the following

    1. For patients with detectable and quantifiable marrow plasmacytosis, a reduction of 50% or more in plasma cells as a percentage of nucleated bone marrow cells.
    2. For patients with a detectable monoclonal peak on serum protein electropheresis or urine protein electropheresis, a reduction in the peak height of 50% or more.
    3. For patients with quantifiable urinary kappa or lambda chain concentration, a reduction in daily light chain excretion (concentration x 24-hr urine volume).

Secondary Outcome Measures :
  1. Number of Participants Surviving at 100 Days From Transplant [ Time Frame: 100 Days from transplant date ]
  2. Number of Participants Surviving at 1 Year [ Time Frame: one year from transplant ]
  3. Number of Participants Surviving at 2 Years [ Time Frame: 2 years from transplant ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:


  • Histologically confirmed primary systemic amyloidosis based on the following criteria:

    • Amyloid light-chain disease
    • Deposition of amyloid material by congo red stain showing characteristic green birefringence
    • Monoclonal light chain protein (Bence Jones protein) in the serum or urine, immunohistochemical studies, or serum free light chain assay
    • Evidence of tissue involvement other than carpal tunnel syndrome (i.e., positive immunohistochemical staining of bone marrow demonstrating clonal plasma cells); tissue amyloid deposits with anti-kappa or anti-lambda anti-serum; evidence for a plasma cell dyscrasia by serum/urine or bone marrow; or overwhelmingly convincing clinical features (e.g., macroglossia) associated with other systemic manifestations


  • Southwest Oncology Group performance status 0-1
  • Fertile patients must use effective contraception
  • Left ventricular ejection fraction ≥ 45% by Echocardiogram within the past 60 days
  • diffusion capacity of lung for carbon monoxide ≥ 50%


  • Prior chemotherapy with alkylating agent allowed provided there is no morphological or cytogenetic evidence of myelodysplastic syndromes
  • Prior total cumulative dose of oral melphalan < 300 mg
  • At least 4 weeks since prior cytotoxic therapy and fully recovered

Exclusion criteria:

  • No senile, secondary, localized, dialysis-related, or familial amyloidosis
  • No overt multiple myeloma (> 30% of bone marrow plasmacytosis, extensive [> 2] lytic lesions, or hypercalcemia)
  • Not pregnant or nursing
  • No myocardial infarction within the past 6 months, congestive heart failure, or arrhythmia refractory to therapy
  • No prior malignancy except for any of the following:

    • Adequately treated basal cell or squamous cell skin cancer
    • In situ cervical cancer
    • Adequately treated stage I or II cancer currently in complete remission
    • Any cancer from which the patient has been disease-free ≥ 5 years
  • No advanced (grade 3-4) pre-existing neuropathy
  • No HIV positivity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00790647

Layout table for location information
United States, Massachusetts
Boston University Cancer Research Center
Boston, Massachusetts, United States, 02118
Sponsors and Collaborators
Boston Medical Center
Layout table for investigator information
Principal Investigator: Vaishali Sanchorawala, MD Boston Medical Center
Layout table for additonal information
Responsible Party: Vaishali Sanchorawala, Principal Investigator, Boston Medical Center Identifier: NCT00790647    
Other Study ID Numbers: CDR0000618857
BUMC-H-27277 ( Other Identifier: Boston University Medical Center IRB )
First Posted: November 13, 2008    Key Record Dates
Results First Posted: February 6, 2017
Last Update Posted: February 6, 2017
Last Verified: December 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Vaishali Sanchorawala, Boston Medical Center:
primary systemic amyloidosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Immunoglobulin Light-chain Amyloidosis
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Proteostasis Deficiencies
Metabolic Diseases
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Immunosuppressive Agents